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Objective. To determine if the BILAG-2004 index is sensitive to change for assessment of SLE disease activity.
Methods. This was a prospective multi-centre longitudinal study of SLE patients. At every assessment, data were collected on disease
activity (BILAG-2004 index) and treatment. Analyses were performed using overall BILAG-2004 index score (as determined by the highest
score achieved by any of the individual systems) and all the systems scores. Sensitivity to change was assessed by determining the
relationship between change in disease activity and change in therapy between two consecutive visits. Statistical analyses were performed
using multinomial logistic regression.
Results. There were 1761 assessments from 347 SLE patients that contributed 1414 observations for analysis. An increase in therapy
between visits occurred in 22.7% observations, while 37.3% had a decrease in therapy and in 40.0% therapy was unchanged. Increase in
overall BILAG-2004 index score was associated with increase in therapy and inversely associated with decrease in therapy. Decrease
in overall BILAG-2004 index score was associated with decrease in therapy and was inversely associated with increase in therapy. Changes
in overall BILAG-2004 index score were differentially related to change in therapy, with greater change in score having greater predictive
power. Increase in the scores of most systems was independently associated with an increase in treatment and there was no significant
association between decreases in the score of any system with an increase in therapy.
Conclusions. The BILAG-2004 index is sensitive to change and is suitable for use in longitudinal studies of SLE.
KEY WORDS: BILAG-2004, SLE, Outcome measures, Epidemiology, Statistics, Sensitivity to change, Responsiveness, Disease activity.
Introduction
SLE is a multi-system autoimmune disease with diverse immu-
nological and clinical manifestations. The BILAG-2004 index, a
comprehensive composite clinical disease activity index, has been
developed for the assessment of SLE disease activity [1–3]. It has
been demonstrated to be reliable and has construct and criterion
validity [1–3]. However, it needs to be shown to be sensitive to
change before it can be used in longitudinal studies of SLE.
Sensitivity to change or responsiveness of an index implies its
ability to change with time. There are two forms of responsive-
ness: internal and external responsiveness [4]. Internal responsive-
ness is the ability of the index to change over a particular period of
time. Traditional statistical methods that have been used to assess
sensitivity to change of several SLE disease activity indices fall
into this category. The main disadvantage of these methods is
that the changes in the index do not relate to changes in an exter-
nal measure, hence statistically significant change in the index may
occur without corresponding change in clinical status. The
comparison is made at the population level and may not
reflect clinical change at individual patient level. Furthermore,
comparison across studies is difficult as the statistical methods
used are not independent of study design.
External responsiveness refers not just to the ability of the index
to change over time, but also includes how the changes in the
index relate to the corresponding changes in an external reference.
It characterizes the relationship between change in the index and
change in the external reference at the individual patient level. The
result is generalizable across studies allowing for comparison.
Therefore, external responsiveness is a more robust method of
assessing sensitivity to change of an index.
We report on the sensitivity to change of the BILAG-2004
index, using the external responsiveness method, for the assess-
ment of SLE disease activity.
Patients and methods
This longitudinal study involved eight centres in the UK. All
patients met the revised ACR criteria for classification of SLE
[5, 6]. Patients were excluded from the study if they were pregnant,
<18 years of age or unable to give valid consent. This study
received multi-centre research ethical approval from Hull and
East Riding Research Ethics Committee and approval from
local research ethics committees. Written consent was obtained
from all patients. This study was carried out in accordance with
the Declaration of Helsinki.
Patients were followed up prospectively and data (disease activ-
ity using BILAG-2004 index and treatment) were collected for all
consecutive visits/encounters (inpatient or outpatient) that the
patients had with their physicians. The majority of the patients
were also involved in the cross-sectional validation study that has
been reported [3]; however, this longitudinal study was of longer
duration and the analysis was completely different.
BILAG-2004 index (BILAG-2004)
This is an ordinal scale index with items distributed across
nine systems. It was developed based on the principle of the
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five levels (Grade A—very active, Grade B—moderate activity,
Grade C—mild activity, Grade D—no activity but previously
affected and Grade E—no current or previous disease activity).
Changes were made to the scoring of the renal system for
Grades A and B during the progress of this study to improve
the scoring system with regards to proteinuria. The changes
made were:
(i) urine protein dipstick result is superseded by other methods
of urine protein estimation (urine albumin–creatinine ratio,
urine protein–creatinine ratio or 24h urine protein) where
available;
(ii) the threshold for definition of improvement in proteinuria
was reduced from 50 to 25%;
(iii) an additional Category B criterion was added for urine pro-
tein excretion which was of at least 0.5g/day (or equivalent)
that has not improved by at least 25%.
These changes were laboratory based and had no impact on data
collection as it only affected the way renal system score was cal-
culated. The renal system score incorporating these changes was
used in the analysis.
During this study, a few other issues related to the glossary
were noted and minor changes were made to the index after
the completion of this study. Although these changes were not
accounted for in the analysis, they would not have had a major
effect on the results of this study.The revised index (BILAG-2004
index form, glossary and scoring scheme) incorporating all
the above changes is available as supplementary data at
Rheumatology Online.
Change in therapy
As there is no gold standard for disease activity, change in therapy
between consecutive visits was used as the external reference for
change in disease activity in the analysis. Change in therapy was
the change in treatment between two consecutive visits (or the
difference in treatment after the patient was assessed at the
index visit, as compared with the therapy prescribed following
the previous visit).
The medications of interest were immunosuppressives,
anti-malarials, glucocorticoids, biological therapy, topical gluco-
corticoids, topical immunosuppressives, intravenous immunoglo-
bulins, plasmapheresis, anti-coagulation, prasterone, thalidomide
and retinoids.
A robust definition for change in therapy was used with three
categories of changes in therapy defined: ‘no change’, ‘increase in
therapy’ and ‘decrease in therapy’. This definition is similar to the
one used in the criterion validity analysis of the cross-sectional
study [3] and is available as supplementary data (Definition of
Change in Therapy and Table A) at Rheumatology Online.
Statistical analysis
The sensitivity to change of the index was assessed using the
external responsiveness method as outlined by Husted et al. [4].
The extent to which changes in BILAG-2004 score between two
consecutive visits relate to the corresponding changes (actual) in
therapy (external reference) was studied. Therefore, two consecu-
tive visits give rise to one observation. This is different from the
criterion validity analysis of the cross-sectional study which
looked at the correlation between the score of the index and
change in therapy at a single visit [3].
The overall BILAG-2004 score (overall score), as determined
by the highest score achieved by any of the individual systems, was
used in the analysis. Further analysis using all the nine system
scores was also performed. Scores of Grades D and E were
combined as both indicate inactivity.
Maximum likelihood multinomial logistic regression was used
in the analysis, with change in therapy as the outcome variable
and change in BILAG-2004 score as the explanatory variable.
The baseline comparator for change in BILAG-2004 score was
‘no change in score’ or ‘minimal change in score’. In addition to
‘no change in score’, ‘minimal change in score’ also includes
the change from Grade D/E to C, as this change is considered
minor and therapy rarely changes. The baseline comparator for
change in treatment was ‘no change in therapy’. As the association
between change in BILAG-2004 score and change in therapy was
assessed in both directions (increase and decrease), the baseline
comparator for these variables were chosen as such.
The results were reported in coefficients with 95% CIs. As this
was a multinomial regression analysis with ‘no change in therapy’
as the baseline comparator, two separate analyses were involved:
(i) comparison between ‘increase in therapy’ and ‘no change in
therapy’ and
(ii) comparison between ‘decrease in therapy’ and ‘no change in
therapy’.
There was no direct comparison between ‘increase in therapy’ and
‘decrease in therapy’. A coefficient value >0 for a particular cate-
gory of change in BILAG-2004 score within the comparison
between ‘increase in therapy’ and ‘no change in therapy’ indicates
that the change in score category is associated with ‘increase in
therapy’. Inversely, a negative coefficient value (<0) for a partic-
ular category of change in BILAG-2004 score within the compar-
ison between ‘increase in therapy’ and ‘no change in therapy’
indicates that the change in score category is associated with
‘no change in therapy’ (and not with ‘decrease in therapy’) or
equivalently an inverse association with ‘increase in therapy’.
This interpretation applies similarly to the comparison between
‘decrease in therapy’ and ‘no change in therapy’.
As the majority of the patients contributed more than one
observation, independence of observations from the same patient
could not be assumed and robust variance estimation was used [7].
All statistical analyses were performed using Stata for Windows
version 8 (Stata Corporation, TX, USA).
Results
There were 1761 assessments from 347 SLE patients (92.9%
females, 57.9% Caucasian, 20.5% Afro-Caribbean and 19%
South Asian) that contributed 1414 observations for analysis.
The mean age was 40.9 years (S.D. 12.9) and mean disease duration
was 8.2 years (S.D. 7.8). The median duration of follow-up was
11 months (range 1–26) and median number of assessments per
patient was four (range 2–18). Increase in treatment between con-
secutive visits occurred in 22.7% of the observations while 37.3%
had therapy decreased, and in 40.0%, there was no change in
treatment. The distribution of the changes in disease activity
according to BILAG-2004 and change in therapy is available as
supplementary data (Table B) available at Rheumatology Online.
Analysis using overall score
Increase in the overall score was associated with increase in
therapy (coefficient 1.35; 95% CI 1.01, 1.70) and inversely asso-
ciated with decrease in therapy (coefficient  0.44; 95% CI  0.81,
 0.06). Decrease in the overall score was associated with decrease
in therapy (coefficient 0.44; 95% CI 0.16, 0.71) and inversely
associated with increase in therapy (coefficient  0.79; 95% CI
 1.27,  0.32).
When the minor change of score from Grade D/E to C was
excluded from the definition of increase in activity (defined as
minimal change in activity), increase in the overall scores had a
much greater predictive power of increase in therapy (coefficient
2.25; 95% CI 1.81, 2.70).
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was more likely than increase in the score to Grade B to be asso-
ciated with increase in therapy. Decrease in the score to Grade
C/D was much less likely to have increase in treatment than
decrease in the score to Grade B (Table 1). Therefore, changes
in overall score were differentially related to change in therapy,
with greater change in score having greater predictive power.
Analysis using system scores
Similar analysis using all the system scores (instead of overall
score) as explanatory variables for the outcome variable of
change in therapy is summarized in Table 2. Apart from the
ophthalmic, haematological and renal systems, increase in the
scores of the other systems was independently associated with
treatment increase. The association between decrease in the
system score and treatment reduction could not be demonstrated
as consistently. There was no significant association between
decreases in score of any system with increase in therapy.
There were too few observations with an increase in the
ophthalmic system score to demonstrate an association between
increase in score and increase in therapy (Table B of supplemen-
tary data, available at Rheumatology Online). In the haematolog-
ical system, the increases in score were due to minor worsening
of leucopenia, neutropenia or anaemia of chronic disease
(resulting in an increase to Grade B) which were not treated.
There was no occurrence of major haematological manifesta-
tion of active disease in this cohort of patients, such as severe
thrombocytopenia or haemolytic anaemia.
The non-significant association between increase in the renal
system score with treatment increase was due to seven observa-
tions with an increase in the score that had therapy unchanged,
while there were 13 observations with an increase in the score in
which the treatment was increased. In addition, there were
15 observations in which therapy was decreased. Thus, there
were in total 22 observations with an increase in the score to
Grades A/B that were not accompanied by an increase in therapy
(Table B of supplementary data, available at Rheumatology
Online). There were three main reasons for this discrepancy.
First, many of these observations were due to persistent
activity in the renal system. As these patients were assessed
frequently (about every 1–2 months), minor changes in the levels
of proteinuria between consecutive visits led to fluctuations in the
system score between adjacent categories (from Grade B to A or
Grade C to B). For example, a change of urine albumin–creatinine
ratio from 122 to 57mg/mmol and subsequently to 73mg/mmol
on three consecutive visits would result in the score changing from
Grade B to C and finally back to B.
Secondly, active urinary sediments may be intermittently
present during the treatment of lupus nephritis. The absence of
it at one visit followed by the reappearance in the following visit
would result in an increase in the system score by one category.
Finally, some patients had pre-existing damage but developed
superimposed active disease which caused difficulty in distinguish-
ing the contribution of disease activity from damage.
Discussion
This multi-centre longitudinal study is the largest prospective vali-
dation study to date assessing the sensitivity to change of a SLE
disease activity index as compared with previous studies of other
disease activity indices [8–13]. As external responsiveness method
was used, changes in both directions (increase and decrease) with
regards to the index score and change in therapy (external refer-
ence) were assessed. It is imperative that the selected external
reference measure represents an accepted indicator of change in
the patient’s status. As change in therapy was chosen as the exter-
nal reference, clinically meaningful change in the index was
studied. Physician’s global assessment could have been used, but
this has performed unsatisfactorily with poor agreement between
physicians in several studies [10, 14, 15].
This study has demonstrated that the BILAG-2004 index is
sensitive to change. There was a hierarchical effect of the different
subgroups of changes in the index score in its association with
TABLE 1. Analysis of the subgroups of changes in overall BILAG-2004 index score
and its association with change in therapy using multinomial logistic regression
(n¼1414)
Change in
overall
BILAG-2004
score
Number of
observations
Increase in
therapy
a
coefficient
(95% CI)
Decrease in
therapy
a
coefficient
(95% CI)
Minimal change in
activity
848 0 0
Increase in activity
to Grade A
48 2.86 (1.85, 3.86)  0.88 ( 2.55, 0.78)
Increase in activity
to Grade B
147 2.07 (1.59, 2.56)  0.14 ( 0.69, 0.41)
Decrease in activity
to Grade B
41  0.37 ( 1.33, 0.59) 0.37 ( 0.28, 1.01)
Decrease in activity
to Grade C or D
330  0.77 ( 1.27,  0.27) 0.51 (0.24, 0.79)
aAs compared with ‘no change in therapy’.
TABLE 2. Sensitivity to change analysis of the BILAG-2004 index using system
scores with multinomial logistic regression after excluding change of Grade D/E
to C from definition of increase in activity (n¼1414)
Change in
BILAG-2004
system score
Number of
observations
Increase in
therapy
a
coefficient
(95% CI)
Decrease in
therapy
a
coefficient
(95% CI)
Constitutional
Minimal change 1339 0 0
Increase 11 1
b 0.02 ( 0.35, 0.38)
Decrease 64 0.36 ( 0.68, 1.40) 0.81 (0.22, 1.39)
Mucocutaneous
Minimal change 991 0 0
Increase 119 2.32 (1.80, 2.84)  0.60 ( 1.32, 0.12)
Decrease 304  0.13 ( 0.54, 0.29) 0.46 (0.17, 0.75)
Neuropsychiatric
Minimal change 1373 0 0
Increase 13 1
b 0.57 ( 1.79, 2.93)
Decrease 28 0.08 ( 1.39, 1.55) 0.75 ( 0.05, 1.55)
Musculoskeletal
Minimal change 1034 0 0
Increase 88 2.94 (2.19, 3.70)  0.04 ( 1.00, 0.91)
Decrease 292  0.28 ( 0.70, 0.14)  0.01 ( 0.33, 0.31)
Cardiorespiratory
Minimal change 1302 0 0
Increase 35 1.25 (0.23, 2.26)  0.41 ( 1.46, 0.65)
Decrease 77 0.22 ( 0.65, 1.08) 0.35 ( 0.20, 0.90)
Gastrointestinal
Minimal change 1397 0 0
Increase 6 2.29 ( 0.22, 4.81)  1
c
Decrease 11  0.11 ( 1.40, 1.17) 0.10 ( 1.23, 1.44)
Ophthalmic
Minimal change 1400 0 0
Increase 4 0.03 ( 5.76, 5.83)  1
d
Decrease 10 1.39 ( 0.58, 3.36) 0.48 ( 1.40, 2.37)
Renal
Minimal change 1313 0 0
Increase 35 1.11 ( 0.01, 2.22) 0.87 ( 0.23, 1.97)
Decrease 66  0.07 ( 0.87, 0.73) 0.57 (0.05, 1.10)
Haematological
Minimal change 1219 0 0
Increase 17  0.01 ( 1.36, 1.37)  0.03 ( 1.04, 0.98)
Decrease 178 0.02 ( 0.51, 0.54)  0.13 ( 0.48, 0.22)
aAs compared with ‘no change in therapy’.
bAll observations had increase in therapy
and coefficient significantly >0( P<0.05).
cAll observations did not have decrease in therapy
and coefficient significantly <0( P<0.05).
dAll observations did not have decrease in therapy but
coefficient not significantly different from 0 (P 0.05).
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predictive power of change in therapy. Furthermore, increases in
the score in most of the systems were independently associated
with increase in therapy and decreases in score in all the systems
were not associated with treatment increase. All of this indicated
that the changes in the index score had performed as expected,
with the possible exception of the renal system. The results may
suggest that the index appears to perform better at detecting
increase in disease activity (stronger association with treatment
increase) as compared with improvement in disease activity in
its association with decrease in therapy. However, this may be
because decrease in therapy is not a good marker of improvement
in disease activity. In practice, increase in therapy is very likely to
occur with increase in disease activity and is unlikely to occur
with decreasing disease activity. The reverse does not hold true
as reduction in disease activity does not necessarily result in treat-
ment reduction, particularly if the patient is already on low-dose
therapy, as there are other important factors to be considered such
as risk of flares if therapy is reduced further. Hence, the relation-
ship between disease activity and increase in therapy is possibly
more informative than that of disease activity with decrease in
therapy.
With change in therapy as the reference standard, we could not
establish definitively that this index is adequately responsive to
improvement in disease activity from very active to moderately
active (Grade A to B) as this degree of change in activity is not
always reflected by a reduction in therapy. This is because an
improvement of the overall score from Grade A to B may occur
in three situations with rather different treatment decisions and
there are insufficient observations to look at each of these sepa-
rately. First, this occurs with improvement in the manifestation
that had resulted in Grade A previously, whereby there would
usually be a reduction or no change in therapy. Another possibil-
ity is when the manifestation that resulted in Grade A previously
has resolved but there is occurrence of another manifestation
within the same system resulting in Grade B. In this situation,
the treatment may be increased or left unchanged. Finally, the
situation arises when the manifestation that resulted in Grade A
has resolved, but there is development of a new Grade B in
another system. With this scenario, it is likely that there will be
an increase in therapy but it may also be left unchanged depending
on the nature of the previous treatment decision. Hence, different
circumstances leading to the change in overall score of Grade A
to B have different likelihood and direction (increase, decrease or
no change) of change in therapy. Nevertheless, we have demon-
strated that major improvement from Grade A/B to C/D is sig-
nificantly associated with decrease in therapy. Furthermore,
clinical trials should use the efficacy criteria of improvement to
low level activity (Grade C/D) as the main outcome, instead of
improvement from Grade A to B.
Some concerns were noted regarding the renal scor-
ing scheme following the completion of the cross-sectional valida-
tion study [3], which were also highlighted in another study on
renal response rating [16]. This resulted in modifications of the
renal scoring system [17]. However, despite these modifications,
the results revealed that the changes in the renal system score
between consecutive visits do not necessarily accord with the
expected change in treatment.
This index is well designed to detect new onset of lupus nephri-
tis or significant resolution of disease activity in the renal system.
However, there is an issue with assessments that are close together
with regards to fluctuations in the level of proteinuria and inter-
mittent active urine sediments during treatment (resulting in fluc-
tuation of the renal system score between adjacent categories of
Grades A and B or Grades B and C). These fluctuations are in fact
persistent disease activity that does not necessarily trigger a
change in treatment. Treatment is not commonly increased on
the basis of a single rise in proteinuria or a single failure of the
proteinuria to improve. Trends over a longer period are more
important in assessing the response of disease activity to a
change in therapy. Another concern is that isolated sterile
pyuria (an element of active urinary sediment) is usually not
treated. Differentiating the contribution of disease activity from
damage in a patient having both processes occurring con-
comitantly remains challenging. Indeed, there is a need for an
effective way to determine whether (and by how much) a renal
manifestation (especially proteinuria) is due to disease activity or
damage without resorting to multiple renal biopsies. All these
issues with the renal system are not specific to the BILAG-2004
index but apply to all disease activity indices.
Although this index was developed on the principle of the
‘physician’s intention to treat’, using change in therapy as the
external reference should not bias the analysis in favour of
the index as change in treatment does not determine the scoring.
Only the presence of manifestations of active disease will deter-
mine the scoring. Furthermore, the scoring of the index was
not available to the physician when the treatment decision was
made and it is difficult to determine the scoring of the index
in routine practice without the appropriate documentation.
It should be noted that actual change in therapy involves con-
sideration of many factors other than change in disease activity
(such as patients’ opinions, previous therapy and presence of
co-morbidities) and this is different from intention to treat
whereby the main consideration is change in disease activity.
Therefore, it is not surprising that change in therapy does not
mirror change in disease activity perfectly.
In conclusion, the BILAG-2004 index is sensitive to change. It
is suitable for use in longitudinal studies of SLE if the outcome of
interest is worsening of disease activity or major improvement in
disease activity to low level of activity. However, further work is
required to confirm that this index is responsive to improve-
ment in disease activity from very active to moderately active.
Furthermore, the issues regarding the renal system (especially
the problem of concomitant disease activity and damage) need
to be considered in longitudinal studies looking at renal outcome,
particularly in clinical trials. We would recommend using more
specific criteria to define response in longitudinal studies on lupus
nephritis. Nevertheless, this index remains very useful in identify-
ing new activity or significant deterioration due to disease activity
in the renal system.
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